|1.||Kashiwagi, Seizaburo: 9 articles (11/2015 - 08/2012)|
|2.||Ikematsu, Hideyuki: 9 articles (11/2015 - 10/2011)|
|3.||Kawai, Naoki: 8 articles (11/2015 - 10/2011)|
|4.||Yamashita, Makoto: 7 articles (10/2013 - 01/2009)|
|5.||Iwaki, Norio: 6 articles (11/2015 - 05/2013)|
|6.||Kubo, Shuku: 6 articles (10/2013 - 01/2009)|
|7.||Hurt, Aeron C: 5 articles (08/2015 - 11/2013)|
|8.||Kakuta, Masayo: 5 articles (10/2013 - 01/2009)|
|9.||Watanabe, Akira: 5 articles (08/2013 - 09/2010)|
|10.||Tomozawa, Takanori: 4 articles (10/2013 - 01/2009)|
06/01/2014 - "After inhaled administration, LO exhibits clinical efficacy for both treatment and prophylaxis of influenza virus infection, resulting from hydrolytic bioactivation into its pharmacologically active metabolite laninamivir in the pulmonary tissue. "
01/01/2013 - "The objectives of this study were to model the population pharmacokinetics of LO and its active metabolite laninamivir after inhaled administration of LO using a pooled population of healthy subjects, and adult and pediatric patients with influenza virus infection from 8 clinical studies, and to evaluate covariate effects on pharmacokinetics. "
04/01/2013 - "Despite laninamivir requiring only the administration of a single dose, it was confirmed to be an effective treatment in more than 90 % of patients with type A or type B influenza virus infections. "
07/01/2012 - "ELF concentration profiles of laninamivir support its long-lasting effect for treatment of patients with influenza virus infection by a single inhaled administration."
08/01/2015 - "Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection."
|2.||Human Influenza (Influenza)
02/01/2014 - "These results show that laninamivir was effective for the treatment of both influenza A(H3N2) and B in this study, with no safety issues. "
12/01/2014 - "These results suggest that laninamivir continued to be effective against influenza A(H3N2) with no safety issues and that it is unlikely that the clinical use of laninamivir will lead to virus resistance."
11/01/2015 - "These results indicate the continuing clinical utility of laninamivir against influenza, irrespective of the virus type/subtype or lineage, and that it is unlikely that the clinical use of laninamivir will lead to selection of resistant virus. "
12/01/2014 - "Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons."
10/01/2014 - "A retrospective review of pregnancy outcomes of 112 pregnant women who were given laninamivir for treatment of influenza was performed. "
|3.||Body Weight (Weight, Body)
01/01/2013 - "Body weight was identified to affect distribution volumes of LO and laninamivir and the metabolic clearance of LO; however there was no notable effect on exposures across the wide body weight range evaluated. "
11/01/2009 - "In this study, the tissue distribution profiles after a single intranasal administration of CS-8958 (0.5 micromol/kg of body weight) to mice were investigated, focusing especially on the retention of CS-8958 in the respiratory tract by comparing it with R-125489 and a marketed drug, zanamivir. "
02/01/2014 - "We investigated the duration of fever and other symptoms after the initiation of laninamivir in the Japanese 2011-2012 influenza season. "
02/01/2014 - "The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season."
05/01/2013 - "The clinical symptoms and duration of fever (body temperature ≥37·5°C) after the first dose of an NAI (oseltamivir, zanamivir, laninamivir) were analyzed. "
01/01/2012 - "In influenza B patients between 5 and 18 years old, the median fever duration after treatment with laninamivir was 3 days, compared with 1 day for peramivir (P = 0.0097). "
01/01/2013 - "Alleviation of fever occurred significantly sooner with peramivir than with either zanamivir (p = 0.0002) or oseltamivir (p = 0.0059), but was not significantly different from that with laninamivir (p = 0.0457; p < 0.0083). "
|5.||Influenza in Birds (Avian Flu)
10/01/2011 - "The effectiveness of laninamivir against the highly pathogenic avian influenza virus H5N1 has also been shown in vitro and in animal models. "
01/01/2010 - "Laninamivir potently inhibited the neuraminidase activities of various influenza A and B viruses, including subtypes N1-N9, pandemic (2009) H1N1 virus, highly pathogenic avian influenza (HPAI) H5N1 viruses and oseltamivir-resistant viruses. "
|1.||caprylic acid (octanoate)
|7.||Antiviral Agents (Antivirals)
|9.||cidofovir hexadecyloxypropyl ester
|10.||DNA Primase (Primase)